ELKTON, Md., May 2, 2017 /PRNewswire/ -- Aragen Bioscience Inc. ("Aragen") will be presenting a poster titled "A Platform to Rapidly Purify and Formulate Immunoglobulins from Mammalian Expression Systems" at the 13th Annual Protein Engineering Summit (PEGS). The platform features the new GORE™ Protein Capture Device with Protein A for rapid mAb purification, as well as other technologies. The Gore pre-packed membrane chromatography column was selected because it offered Aragen something different— the advantage of high post-purification eluent concentration versus traditional agarose technology. Rene Pagila, a Scientist at Aragen Bioscience Inc commented:
"Our typical steps to purify, formulate and analyze human IgG from transient system cultures can take multiple days to complete and can vary greatly depending on many factors. It involves quite a few steps— clarification of harvested cell culture fluid, affinity purification using Protein A, polishing steps if required, a combination of dialysis and concentration steps using centrifugal filter units for formulation, and the assessment of the formulated antibody product for purity and other biophysical characteristics. Recently introduced technologies such as Protein A membrane devices and TFF systems capable of handling ultrafiltration and diafiltration of samples as low as 1.0 mL have tremendously decreased the turnaround time down by 2-3 days, depending on the process. Given that we purify hundreds of antibodies each year, this technology will provide significant process efficiencies to our production efforts".
Aragen Bioscience Inc. is a leading contract research organization (CRO) focused on accelerating product development through high quality science, professionalism, and innovation. Their integrated preclinical research offerings include: antibody discovery, antibody humanization, recombinant protein production and purification, cell-based and in vivo models of disease assays, and stable cell line development.
Gore Product Specialist for Chromatography Products William Barrett, Ph.D. added, "The Gore message that resonates most with the industry is the combination of capacity and speed along with the potential to eliminate a concentration step. Gore is very pleased with the positive feedback for our new line from Aragen Biosicence as well as other top protein science researchers."
About Gore's New Protein Capture Devices
Gore's new line of Protein Capture Devices with Protein A fundamentally improves the purification process of monoclonal antibodies. GORE™ Protein Capture Devices use a unique expanded polytetrafluoroethylene (ePTFE) membrane composite that provides a binding capacity advantage at high flow rates and improves the speed of purification. These unique membrane devices are offered in 1.0 mL (≥ 30 mg capacity) and 3.5 mL (≥ 105 mg capacity).
Unlike other resin-based columns, the GORE Protein Capture Device has higher binding capacity at a short residence time, enabling faster processing times and potential for more highly concentrated elution pools. This allows researchers to screen more candidates in less time and potentially eliminate a downstream concentration step during the antibody purification process.
To learn more about GORE Protein Capture Devices, visit https://www.gore.com/products/categories/pharmaceutical-biopharmaceutical?view=chromatography.
W. L. Gore & Associates is a global materials science company dedicated to transforming industries and improving lives. Founded in 1958, Gore has built a reputation for solving complex technical challenges in the most demanding environments — from revolutionizing the outerwear industry with GORE-TEX® fabric to creating medical devices that improve and save lives to enabling new levels of performance in the aerospace, pharmaceutical and mobile electronics markets, among other industries. The company is also known for its strong, team-oriented culture and continued recognition from the Great Place to Work® Institute. Headquartered in Newark, Del., Gore employs approximately 10,000 associates and generates annual revenues that exceed $3 billion. www.gore.com
About Gore PharmBIO Products
Our technologies, capabilities, and competencies in fluoropolymer science are focused on satisfying the evolving product, regulatory, and quality needs of pharmaceutical and bioprocessing customers, and medical device manufacturers. GORE Protein Capture Devices, like all products in the Gore PharmBIO Products portfolio, are tested and manufactured under stringent quality systems. These high-performance products provide creative solutions to our customers' design, manufacturing, and performance-in-use needs.
What is e-PTFE?
What differentiates Gore's life sciences solutions is our use of advanced materials — particularly expanded polytetrafluoroethylene or ePTFE — and our expertise in modifying those materials for each application. ePTFE is inherently breathable, bio-inert, porous, and non-particulating to name just a few of its properties. These unique properties enable our products to perform more efficiently while often taking smaller, lighter, or stronger forms. In each application, Gore has the ability to manipulate ePTFE and combine it with other high performance materials and technologies to exhibit the properties needed to provide peak functionality.
For more information contact:
Liz Guiney, Marketing Communications, Gore, firstname.lastname@example.org
Susan Stipa, Media Contact, McDay, email@example.com
For more information, please visit gore.com/pharmbio
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/gore-protein-capture-device-drives-timeline-reduction-for-cro-300449921.html
SOURCE W.L. Gore